Supplementary Tables – Real-world treatment patterns and overall survival in BRAF-mutant melanoma patients treated with immunotherapy or targeted therapy

<strong>Sensitivity analysis 1: Statistical adjustment without inverse probability of treatment weighting (IPTW)</strong> <strong>Sensitivity analysis 2: Censoring patients in the practice subanalysis who initiate a therapy off-sequence</strong> <strong>Sensitivity analysis 3: Restricting to CPI patients receiving ipilimumab + nivolumab</strong> <strong>Supplemental Table 1. </strong>Comparison of statistical adjustments with and without inverse probability of treatment weighting (IPTW). <strong>Supplemental Table 2. </strong>Baseline Characteristics of Patients With Advanced <em>BRAF-</em>Mt Melanoma by 1L Treatment